{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:14:32Z","timestamp":1788488072119,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Science and Technology Council, Taiwan","award":["NSTC112-2314-B-038-054-MY3"],"award-info":[{"award-number":["NSTC112-2314-B-038-054-MY3"]}]},{"name":"National Science and Technology Council, Taiwan","award":["NSTC114-2314-B-038-116-MY3"],"award-info":[{"award-number":["NSTC114-2314-B-038-116-MY3"]}]},{"name":"National Science and Technology Council, Taiwan","award":["NSTC112-2314-B-038-126-MY3"],"award-info":[{"award-number":["NSTC112-2314-B-038-126-MY3"]}]},{"name":"Chi Mei Medical Center, Taiwan","award":["112CM-TMU-02"],"award-info":[{"award-number":["112CM-TMU-02"]}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes, Taiwan","doi-asserted-by":"crossref","award":["NHRI-EX115-11414BI"],"award-info":[{"award-number":["NHRI-EX115-11414BI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02977-y","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:04:47Z","timestamp":1780873487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Co-targeting EGFR and SUCLG2 disrupts a nuclear transcriptional program driving neuroendocrine differentiation and TKI resistance in castration-resistant prostate cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Wei-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Kajla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Kun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Ching","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phan Vu Thuy","family":"Dung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Lien","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Ching","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Ru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoti","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Nien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2977_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2977_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, et al. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis. JAMA Oncol. 2023;9:635\u201345.","journal-title":"JAMA Oncol"},{"key":"2977_CR3","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019;25:6916\u201324.","journal-title":"Clin Cancer Res"},{"key":"2977_CR4","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1038\/emboj.2011.158","volume":"30","author":"CE Massie","year":"2011","unstructured":"Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30:2719\u201333.","journal-title":"EMBO J"},{"key":"2977_CR5","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1038\/s41598-020-60384-w","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Ma S, Ruzzo WL. Spatial modeling of prostate cancer metabolic gene expression reveals extensive heterogeneity and selective vulnerabilities. Sci Rep. 2020;10:3490.","journal-title":"Sci Rep"},{"key":"2977_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","volume":"41","author":"L Merkens","year":"2022","unstructured":"Merkens L, Sailer V, Lessel D, Janzen E, Greimeier S, Kirfel J, et al. Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. J Exp Clin Cancer Res. 2022;41:46.","journal-title":"J Exp Clin Cancer Res"},{"key":"2977_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","volume":"150","author":"W Yang","year":"2012","unstructured":"Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012;150:685\u201396.","journal-title":"Cell"},{"key":"2977_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.molcel.2016.02.009","volume":"61","author":"X Li","year":"2016","unstructured":"Li X, Jiang Y, Meisenhelder J, Yang W, Hawke DH, Zheng Y, et al. Mitochondria-translocated PGK1 functions as a protein kinase to coordinate glycolysis and the TCA cycle in tumorigenesis. Mol Cell. 2016;61:705\u201319.","journal-title":"Mol Cell"},{"key":"2977_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"2977_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.tibs.2016.05.013","volume":"41","author":"AE Boukouris","year":"2016","unstructured":"Boukouris AE, Zervopoulos SD, Michelakis ED. Metabolic enzymes moonlighting in the nucleus: metabolic regulation of gene transcription. Trends Biochem Sci. 2016;41:712\u201330.","journal-title":"Trends Biochem Sci"},{"key":"2977_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-biochem-030122-044718","volume":"94","author":"JA van der Knaap","year":"2025","unstructured":"van der Knaap JA, Verrijzer CP. Moonlighting enzymes at the interface between metabolism and epigenetics. Annu Rev Biochem. 2025;94:279\u2013303.","journal-title":"Annu Rev Biochem"},{"key":"2977_CR12","doi-asserted-by":"crossref","unstructured":"Kourtis S, Ga\u00f1ez Zapater A, Elb\u00e6k CR, Schmidt A, Ghose R, Coll Manzano A, Espinar Calvo L, Guirola M, Pardo-Lorente N, Garcia-Cao M, et al. Native chromatome profiling reveals hundreds of metabolic enzymes in the nucleus across tissues. Nat Commun. 2026;17:1655.","DOI":"10.1038\/s41467-026-69217-2"},{"key":"2977_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","volume":"125","author":"F Ahmad","year":"2021","unstructured":"Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. Br J Cancer. 2021;125:1185\u201396.","journal-title":"Br J Cancer"},{"key":"2977_CR14","doi-asserted-by":"publisher","first-page":"882906","DOI":"10.3389\/fendo.2022.882906","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Chen D, Pang Y, Xu X, Guan X, Liu L. Value of immunohistochemical expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in differentiating metastatic from non-metastatic pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2022;13:882906.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2977_CR15","doi-asserted-by":"publisher","first-page":"e2303535","DOI":"10.1002\/advs.202303535","volume":"10","author":"Q Hu","year":"2023","unstructured":"Hu Q, Xu J, Wang L, Yuan Y, Luo R, Gan M, et al. SUCLG2 regulates mitochondrial dysfunction through succinylation in lung adenocarcinoma. Adv Sci (Weinh). 2023;10:e2303535.","journal-title":"Adv Sci (Weinh)"},{"key":"2977_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41467-019-13668-3","volume":"11","author":"I Mart\u00ednez-Reyes","year":"2020","unstructured":"Mart\u00ednez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11:102.","journal-title":"Nat Commun"},{"key":"2977_CR17","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.1038\/s41388-020-01468-9","volume":"39","author":"SR Lin","year":"2020","unstructured":"Lin SR, Wen YC, Yeh HL, Jiang KC, Chen WH, Mokgautsi N, et al. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer. Oncogene. 2020;39:6757\u201375.","journal-title":"Oncogene"},{"key":"2977_CR18","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/sj.bjc.6605376","volume":"101","author":"AM Traish","year":"2009","unstructured":"Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009;101:1949\u201356.","journal-title":"Br J Cancer"},{"key":"2977_CR19","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1038\/sj.onc.1210983","volume":"27","author":"CQ Cai","year":"2008","unstructured":"Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene. 2008;27:3201\u201310.","journal-title":"Oncogene"},{"key":"2977_CR20","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1158\/1078-0432.CCR-07-1257","volume":"13","author":"T Schlomm","year":"2007","unstructured":"Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res. 2007;13:6579\u201384.","journal-title":"Clin Cancer Res"},{"key":"2977_CR21","first-page":"3438","volume":"8","author":"G Di Lorenzo","year":"2002","unstructured":"Di Lorenzo G, Tortora G, D\u2019Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002;8:3438\u201344.","journal-title":"Clin Cancer Res"},{"key":"2977_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1464-410X.2007.07121.x","volume":"100","author":"EJ Small","year":"2007","unstructured":"Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007;100:765\u20139.","journal-title":"BJU Int"},{"key":"2977_CR23","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3892\/ijo.2012.1509","volume":"41","author":"D Carri\u00f3n-Salip","year":"2012","unstructured":"Carri\u00f3n-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, et al. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol. 2012;41:1128\u201338.","journal-title":"Int J Oncol"},{"key":"2977_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/carcin\/bgs139","volume":"33","author":"MA Cort\u00e9s","year":"2012","unstructured":"Cort\u00e9s MA, Cariaga-Martinez AE, Lobo MV, Mart\u00edn Orozco RM, Moti\u00f1o O, Rodr\u00edguez-Ubreva FJ, et al. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. Carcinogenesis. 2012;33:1169\u201377.","journal-title":"Carcinogenesis"},{"key":"2977_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3389\/fonc.2018.00347","volume":"8","author":"HF Bahmad","year":"2018","unstructured":"Bahmad HF, Cheaito K, Chalhoub RM, Hadadeh O, Monzer A, Ballout F, et al. Sphere-formation assay: three-dimensional in vitro culturing of prostate cancer stem\/progenitor sphere-forming cells. Front Oncol. 2018;8:347.","journal-title":"Front Oncol"},{"key":"2977_CR26","doi-asserted-by":"crossref","unstructured":"Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, et al. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Sci Transl Med. 2019;11:521.eaax0428.","DOI":"10.1126\/scitranslmed.aax0428"},{"key":"2977_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298\u2013305.","journal-title":"Nat Med"},{"key":"2977_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41467-019-13668-3","volume":"11","author":"I Martinez-Reyes","year":"2020","unstructured":"Martinez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11:102.","journal-title":"Nat Commun"},{"key":"2977_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/sj.bjc.6602941","volume":"94","author":"HW Lo","year":"2006","unstructured":"Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer. 2006;94:184\u20138.","journal-title":"Br J Cancer"},{"key":"2977_CR30","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ncb0901-802","volume":"3","author":"SY Lin","year":"2001","unstructured":"Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001;3:802\u20138.","journal-title":"Nat Cell Biol"},{"key":"2977_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2005.05.007","volume":"7","author":"HW Lo","year":"2005","unstructured":"Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS\/NO pathway. Cancer Cell. 2005;7:575\u201389.","journal-title":"Cancer Cell"},{"key":"2977_CR32","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.1158\/1078-0432.CCR-08-2813","volume":"15","author":"SC Wang","year":"2009","unstructured":"Wang SC, Hung MC. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res. 2009;15:6484\u20139.","journal-title":"Clin Cancer Res"},{"key":"2977_CR33","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171:1437-1452 e1417.","journal-title":"Cell"},{"key":"2977_CR34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/pros.22457","volume":"72","author":"K Sakao","year":"2012","unstructured":"Sakao K, Desineni S, Hahm ER, Singh SV. Phenethyl isothiocyanate suppresses inhibitor of apoptosis family protein expression in prostate cancer cells in culture and in vivo. Prostate. 2012;72:1104\u201316.","journal-title":"Prostate"},{"key":"2977_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3892\/ijo_00000702","volume":"37","author":"LG Wang","year":"2010","unstructured":"Wang LG, Chiao JW. Prostate cancer chemopreventive activity of phenethyl isothiocyanate through epigenetic regulation (review). Int J Oncol. 2010;37:533\u20139.","journal-title":"Int J Oncol"},{"key":"2977_CR36","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/mnfr.201500918","volume":"60","author":"C Zhang","year":"2016","unstructured":"Zhang C, Shu L, Kim H, Khor TO, Wu R, Li W, et al. Phenethyl isothiocyanate (PEITC) suppresses prostate cancer cell invasion epigenetically through regulating microRNA-194. Mol Nutr Food Res. 2016;60:1427\u201336.","journal-title":"Mol Nutr Food Res"},{"key":"2977_CR37","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1021\/acsptsci.4c00301","volume":"7","author":"S Guin","year":"2024","unstructured":"Guin S, Ashokan A, Pollack A, Dhar S. Lipid metabolism modulatory cisplatin prodrug sensitizes resistant prostate cancer toward androgen deprivation therapy. ACS Pharmacol Transl Sci. 2024;7:2820\u20136.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2977_CR38","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"2977_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11\u201322.","journal-title":"Cancer Cell"},{"key":"2977_CR40","doi-asserted-by":"publisher","first-page":"110595","DOI":"10.1016\/j.celrep.2022.110595","volume":"39","author":"H Han","year":"2022","unstructured":"Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, et al. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep. 2022;39:110595.","journal-title":"Cell Rep"},{"key":"2977_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"\u00c1 Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga \u00c1, Chan JM, Yu HA, Pe\u2019er D, Sawyers CL, Sen T, et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020;17:360\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"2977_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7:77\u201385.","journal-title":"Cancer Cell"},{"key":"2977_CR43","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1101\/gad.191056.112","volume":"26","author":"M Xiao","year":"2012","unstructured":"Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of \u03b1-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26:1326\u201338.","journal-title":"Genes Dev"},{"key":"2977_CR44","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/jcb.20876","volume":"98","author":"HW Lo","year":"2006","unstructured":"Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem. 2006;98:1570\u201383.","journal-title":"J Cell Biochem"},{"key":"2977_CR45","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1091\/mbc.e06-09-0802","volume":"18","author":"HJ Liao","year":"2007","unstructured":"Liao HJ, Carpenter G. Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol Biol Cell. 2007;18:1064\u201372.","journal-title":"Mol Biol Cell"},{"key":"2977_CR46","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.molcel.2008.08.007","volume":"31","author":"D Chuderland","year":"2008","unstructured":"Chuderland D, Konson A, Seger R. Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol Cell. 2008;31:850\u201361.","journal-title":"Mol Cell"},{"key":"2977_CR47","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cmet.2024.11.005","volume":"37","author":"R Liu","year":"2025","unstructured":"Liu R, Ren X, Park YE, Feng H, Sheng X, Song X, et al. Nuclear GTPSCS functions as a lactyl-CoA synthetase to promote histone lactylation and gliomagenesis. Cell Metab. 2025;37:377-394.e379.","journal-title":"Cell Metab"},{"key":"2977_CR48","doi-asserted-by":"publisher","first-page":"eade5855","DOI":"10.1126\/scitranslmed.ade5855","volume":"15","author":"M Wang","year":"2023","unstructured":"Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, et al. Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Sci Transl Med. 2023;15:eade5855.","journal-title":"Sci Transl Med"},{"key":"2977_CR49","doi-asserted-by":"publisher","first-page":"e25156","DOI":"10.4161\/onci.25156","volume":"2","author":"M Terme","year":"2013","unstructured":"Terme M, Tartour E, Taieb J. VEGFA\/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer. Oncoimmunology. 2013;2:e25156.","journal-title":"Oncoimmunology"},{"key":"2977_CR50","doi-asserted-by":"crossref","unstructured":"Zhang Y, Huang H, Coleman M, Ziemys A, Gopal P, Kazmi SM, Brekken RA. VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. JCI Insight. 2021;6:23.e150735.","DOI":"10.1172\/jci.insight.150735"},{"key":"2977_CR51","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.molcel.2019.10.023","volume":"77","author":"JY Wu","year":"2020","unstructured":"Wu JY, Huang TW, Hsieh YT, Wang YF, Yen CC, Lee GL, et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via Succinate Receptor. Mol Cell. 2020;77:213-227.e215.","journal-title":"Mol Cell"},{"key":"2977_CR52","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1172\/JCI20465","volume":"113","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040\u201350.","journal-title":"J Clin Invest"},{"key":"2977_CR53","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","volume":"2","author":"N Ferrara","year":"2002","unstructured":"Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795\u2013803.","journal-title":"Nat Rev Cancer"},{"key":"2977_CR54","first-page":"3615","volume":"62","author":"D Xiao","year":"2002","unstructured":"Xiao D, Singh SV. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res. 2002;62:3615\u20139.","journal-title":"Cancer Res"},{"key":"2977_CR55","doi-asserted-by":"publisher","first-page":"e26615","DOI":"10.1371\/journal.pone.0026615","volume":"6","author":"SH Kim","year":"2011","unstructured":"Kim SH, Sehrawat A, Sakao K, Hahm ER, Singh SV. Notch activation by phenethyl isothiocyanate attenuates its inhibitory effect on prostate cancer cell migration. PLoS One. 2011;6:e26615.","journal-title":"PLoS One"},{"key":"2977_CR56","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1039\/C7FO01983A","volume":"9","author":"H Huang","year":"2018","unstructured":"Huang H, He Y, Zhang L, Xiang H, Li D, Liu W, et al. Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgen-independent growth of prostate cancer cells. Food Funct. 2018;9:2398\u2013408.","journal-title":"Food Funct"},{"key":"2977_CR57","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","volume":"9","author":"L Puca","year":"2018","unstructured":"Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018;9:2404.","journal-title":"Nat Commun"},{"key":"2977_CR58","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355:84\u20138.","journal-title":"Science"},{"key":"2977_CR59","doi-asserted-by":"publisher","first-page":"T67","DOI":"10.1530\/ERC-21-0140","volume":"28","author":"H Beltran","year":"2021","unstructured":"Beltran H, Demichelis F. Therapy considerations in neuroendocrine prostate cancer: what next? Endocr Relat Cancer. 2021;28:T67-t78.","journal-title":"Endocr Relat Cancer"},{"key":"2977_CR60","first-page":"3753","volume":"51","author":"M Gleave","year":"1991","unstructured":"Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 1991;51:3753\u201361.","journal-title":"Cancer Res"},{"key":"2977_CR61","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2977_CR62","doi-asserted-by":"publisher","first-page":"11389","DOI":"10.1158\/0008-5472.CAN-06-2318","volume":"66","author":"S Kobayashi","year":"2006","unstructured":"Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006;66:11389\u201398.","journal-title":"Cancer Res"},{"key":"2977_CR63","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487\u201395.","journal-title":"Cancer Discov"},{"key":"2977_CR64","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.","journal-title":"Nat Commun"},{"key":"2977_CR65","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock SL, Lopez R, Klein AM. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 2019;8:281-291 e289.","journal-title":"Cell Syst"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02977-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02977-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02977-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:02:24Z","timestamp":1788487344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02977-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2977"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02977-y","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"474"}}